|
2024-03-08 |
2024-03-08 |
PS
Planned sale
|
Tourangeau Greg
Vice President, Finance
Officer
|
4,884
-29.3%
11.72
57,219
USD
|
4,884
-29.3%
|
11.72
|
57,219
USD
|
|
|
2024-03-05 |
2024-03-04 |
B
Purchase
|
Sapir Alex
See Remarks
Executive Director
|
43,360
+inf%
11.35
492,028
USD
|
43,360
+inf%
|
11.35
|
492,028
USD
|
|
|
2023-05-11 |
2023-05-10 |
S
Sale
|
Tourangeau Greg
Principal Accounting Officer
Officer
|
210
-1.3%
3.31
695
USD
|
210
-1.3%
|
3.31
|
695
USD
|
|
|
2023-01-24 |
2023-01-20 |
B
Purchase
|
RA CAPITAL MANAGEMENT, L.P.
Major owner
|
1,923,076
+19.9%
13.00
24,999,988
USD
|
1,923,076
+19.9%
|
13.00
|
24,999,988
USD
|
|
|
2023-01-13 |
2023-01-13 |
PS
Planned sale
|
Gould Robert J
Interim President & CEO
Executive Director
|
6,766
-1.3%
15.00
101,490
USD
|
6,766
-1.3%
|
15.00
|
101,490
USD
|
|
|
2023-01-06 |
2023-01-04 |
B
Purchase
|
RA CAPITAL MANAGEMENT, L.P.
Major owner
|
58,369
+0.6%
7.80
455,091
USD
|
58,369
+0.6%
|
7.80
|
455,091
USD
|
|
|
2023-01-06 |
2023-01-04 |
B
Purchase
|
RA CAPITAL MANAGEMENT, L.P.
Major owner
|
122,334
+1.3%
7.03
859,714
USD
|
122,334
+1.3%
|
7.03
|
859,714
USD
|
|
|
2022-12-29 |
2022-12-27 |
B
Purchase
|
RA CAPITAL MANAGEMENT, L.P.
Major owner
|
4,089
+0.0%
5.99
24,510
USD
|
4,089
+0.0%
|
5.99
|
24,510
USD
|
|
|
2022-12-21 |
2022-12-19 |
B
Purchase
|
RA CAPITAL MANAGEMENT, L.P.
Major owner
|
98,787
+1.1%
5.90
582,814
USD
|
98,787
+1.1%
|
5.90
|
582,814
USD
|
|
|
2022-12-16 |
2022-12-16 |
B
Purchase
|
RA CAPITAL MANAGEMENT, L.P.
Major owner
|
1,341,420
+16.6%
5.42
7,269,826
USD
|
1,341,420
+16.6%
|
5.42
|
7,269,826
USD
|
|
|
2022-12-16 |
2022-12-15 |
B
Purchase
|
RA CAPITAL MANAGEMENT, L.P.
Major owner
|
237,029
+3.0%
5.50
1,302,474
USD
|
237,029
+3.0%
|
5.50
|
1,302,474
USD
|
|
|
2022-12-16 |
2022-12-14 |
B
Purchase
|
RA CAPITAL MANAGEMENT, L.P.
Major owner
|
824,600
+11.8%
5.46
4,501,574
USD
|
824,600
+11.8%
|
5.46
|
4,501,574
USD
|
|
|
2022-06-08 |
2022-06-07 |
PS
Planned sale
|
Gould Robert J
Non-Executive Director
|
71,435
-12.4%
8.09
577,895
USD
|
71,435
-12.4%
|
8.09
|
577,895
USD
|
|
|
2022-06-06 |
2022-06-06 |
PS
Planned sale
|
Gould Robert J
Non-Executive Director
|
24,382
-4.6%
8.10
197,592
USD
|
24,382
-4.6%
|
8.10
|
197,592
USD
|
|
|
2022-06-06 |
2022-06-03 |
PS
Planned sale
|
Gould Robert J
Non-Executive Director
|
25,551
-4.8%
7.95
203,056
USD
|
25,551
-4.8%
|
7.95
|
203,056
USD
|
|
|
2022-06-06 |
2022-06-02 |
PS
Planned sale
|
Gould Robert J
Non-Executive Director
|
16,689
-3.2%
7.92
132,162
USD
|
16,689
-3.2%
|
7.92
|
132,162
USD
|
|
|
2022-04-11 |
2022-04-07 |
PS
Planned sale
|
Gould Robert J
Non-Executive Director
|
5,631
-1.1%
24.02
135,228
USD
|
5,631
-1.1%
|
24.02
|
135,228
USD
|
|
|
2022-04-05 |
2022-04-05 |
PS
Planned sale
|
Gould Robert J
Non-Executive Director
|
52,552
-9.4%
24.26
1,274,775
USD
|
52,552
-9.4%
|
24.26
|
1,274,775
USD
|
|
|
2022-04-05 |
2022-04-04 |
PS
Planned sale
|
Gould Robert J
Non-Executive Director
|
7,235
-1.4%
24.02
173,749
USD
|
7,235
-1.4%
|
24.02
|
173,749
USD
|
|
|
2022-04-05 |
2022-04-01 |
PS
Planned sale
|
Gould Robert J
Non-Executive Director
|
34,464
-6.4%
24.03
828,160
USD
|
34,464
-6.4%
|
24.03
|
828,160
USD
|
|
|
2021-08-12 |
2021-08-11 |
PS
Planned sale
|
Stuart Bryan
See Remarks
Executive Director
|
28,000
-100.0%
23.75
665,000
USD
|
28,000
-100.0%
|
23.75
|
665,000
USD
|
|
|
2021-08-12 |
2021-08-10 |
PS
Planned sale
|
Stuart Bryan
See Remarks
Executive Director
|
32,000
-100.0%
17.50
560,000
USD
|
32,000
-100.0%
|
17.50
|
560,000
USD
|
|
|
2021-06-29 |
2021-06-28 |
B
Purchase
|
Oltmans Curtis Gale
SVP, General Counsel
Officer
|
1,088
+inf%
9.01
9,803
USD
|
1,088
+inf%
|
9.01
|
9,803
USD
|
|
|
2021-06-29 |
2021-06-28 |
B
Purchase
|
Thomson Peter G.
VP Finance & Accounting
Officer
|
2,300
+inf%
9.00
20,700
USD
|
2,300
+inf%
|
9.00
|
20,700
USD
|
|
|
2021-06-29 |
2021-06-28 |
B
Purchase
|
Morabito Christopher
Chief Medical Officer
Officer
|
1,100
+inf%
9.16
10,076
USD
|
1,100
+inf%
|
9.16
|
10,076
USD
|
|
|
2021-06-29 |
2021-06-28 |
B
Purchase
|
GERAGHTY JAMES A
Non-Executive Director
|
10,000
+12.4%
9.16
91,600
USD
|
10,000
+12.4%
|
9.16
|
91,600
USD
|
|
|
2021-03-17 |
2021-03-16 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
789
-0.2%
12.43
9,806
USD
|
789
-0.2%
|
12.43
|
9,806
USD
|
|
|
2021-03-17 |
2021-03-15 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
9,211
-1.8%
12.13
111,773
USD
|
9,211
-1.8%
|
12.13
|
111,773
USD
|
|
|
2021-02-24 |
2021-02-22 |
PS
Planned sale
|
Thomson Peter G.
VP Finance & Accounting
Officer
|
5,000
-24.7%
14.72
73,582
USD
|
5,000
-24.7%
|
14.72
|
73,582
USD
|
|
|
2021-02-18 |
2021-02-16 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
1,673
-0.3%
14.56
24,367
USD
|
1,673
-0.3%
|
14.56
|
24,367
USD
|
|
|
2021-02-18 |
2021-02-16 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
6,542
-1.2%
14.19
92,830
USD
|
6,542
-1.2%
|
14.19
|
92,830
USD
|
|
|
2021-01-25 |
2021-01-21 |
PS
Planned sale
|
Thomson Peter G.
VP Finance & Accounting
Officer
|
6,607
-30.3%
14.00
92,498
USD
|
6,607
-30.3%
|
14.00
|
92,498
USD
|
|
|
2021-01-22 |
2021-01-20 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
10,000
-1.9%
12.08
120,826
USD
|
10,000
-1.9%
|
12.08
|
120,826
USD
|
|
|
2020-07-09 |
2020-07-08 |
PS
Planned sale
|
Wallace Owen B.
Chief Scientific Officer
Officer
|
2,951
-2.3%
20.00
59,020
USD
|
2,951
-2.3%
|
20.00
|
59,020
USD
|
|
|
2020-07-09 |
2020-07-08 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
2,500
-0.5%
20.00
50,000
USD
|
2,500
-0.5%
|
20.00
|
50,000
USD
|
|
|
2020-07-02 |
2020-07-01 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
1,071
-1.6%
18.30
19,599
USD
|
1,071
-1.6%
|
18.30
|
19,599
USD
|
|
|
2020-07-01 |
2020-06-30 |
PS
Planned sale
|
Wallace Owen B.
Chief Scientific Officer
Officer
|
141
-0.1%
20.00
2,820
USD
|
141
-0.1%
|
20.00
|
2,820
USD
|
|
|
2020-06-26 |
2020-06-25 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
1,459
-2.1%
22.00
32,098
USD
|
1,459
-2.1%
|
22.00
|
32,098
USD
|
|
|
2020-06-26 |
2020-06-25 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
2,500
-0.5%
20.80
51,992
USD
|
2,500
-0.5%
|
20.80
|
51,992
USD
|
|
|
2020-06-12 |
2020-06-10 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
401
-0.6%
22.00
8,822
USD
|
401
-0.6%
|
22.00
|
8,822
USD
|
|
|
2020-06-10 |
2020-06-09 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
156
-0.0%
20.00
3,120
USD
|
156
-0.0%
|
20.00
|
3,120
USD
|
|
|
2020-06-09 |
2020-06-05 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
3,433
-0.6%
20.17
69,251
USD
|
3,433
-0.6%
|
20.17
|
69,251
USD
|
|
|
2020-06-08 |
2020-06-05 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
451
-0.7%
20.18
9,101
USD
|
451
-0.7%
|
20.18
|
9,101
USD
|
|
|
2020-06-08 |
2020-06-04 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
226
-0.3%
20.05
4,531
USD
|
226
-0.3%
|
20.05
|
4,531
USD
|
|
|
2020-06-05 |
2020-06-04 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
1,300
-0.2%
20.04
26,058
USD
|
1,300
-0.2%
|
20.04
|
26,058
USD
|
|
|
2020-06-05 |
2020-06-03 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
1,500
-0.3%
20.13
30,192
USD
|
1,500
-0.3%
|
20.13
|
30,192
USD
|
|
|
2020-06-04 |
2020-06-03 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
338
-0.5%
20.18
6,820
USD
|
338
-0.5%
|
20.18
|
6,820
USD
|
|
|
2020-06-04 |
2020-06-02 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
45
-0.1%
20.00
900
USD
|
45
-0.1%
|
20.00
|
900
USD
|
|
|
2020-06-03 |
2020-06-02 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
2,797
-0.5%
20.00
55,940
USD
|
2,797
-0.5%
|
20.00
|
55,940
USD
|
|
|
2020-06-03 |
2020-06-01 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
5
-0.0%
20.00
100
USD
|
5
-0.0%
|
20.00
|
100
USD
|
|
|
2020-06-01 |
2020-05-29 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
200
-0.3%
20.04
4,007
USD
|
200
-0.3%
|
20.04
|
4,007
USD
|
|
|
2020-06-01 |
2020-05-29 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
1,390
-0.3%
20.08
27,911
USD
|
1,390
-0.3%
|
20.08
|
27,911
USD
|
|
|
2020-06-01 |
2020-05-28 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
600
-0.9%
20.00
12,000
USD
|
600
-0.9%
|
20.00
|
12,000
USD
|
|
|
2020-06-01 |
2020-05-28 |
PS
Planned sale
|
Wallace Owen B.
Chief Scientific Officer
Officer
|
2,232
-1.7%
20.00
44,640
USD
|
2,232
-1.7%
|
20.00
|
44,640
USD
|
|
|
2020-06-01 |
2020-05-28 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
1,919
-0.3%
20.01
38,391
USD
|
1,919
-0.3%
|
20.01
|
38,391
USD
|
|
|
2020-05-29 |
2020-05-27 |
PS
Planned sale
|
Wallace Owen B.
Chief Scientific Officer
Officer
|
448
-0.4%
20.00
8,960
USD
|
448
-0.4%
|
20.00
|
8,960
USD
|
|
|
2020-05-28 |
2020-05-26 |
PS
Planned sale
|
Wallace Owen B.
Chief Scientific Officer
Officer
|
412
-0.3%
20.00
8,240
USD
|
412
-0.3%
|
20.00
|
8,240
USD
|
|
|
2020-05-28 |
2020-05-26 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
2,500
-0.5%
20.00
50,000
USD
|
2,500
-0.5%
|
20.00
|
50,000
USD
|
|
|
2020-05-12 |
2020-05-12 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
1,860
-2.7%
18.00
33,480
USD
|
1,860
-2.7%
|
18.00
|
33,480
USD
|
|
|
2020-05-12 |
2020-05-11 |
PS
Planned sale
|
Thomson Peter G.
VP Finance & Accounting
Officer
|
7,500
-26.3%
16.00
120,000
USD
|
7,500
-26.3%
|
16.00
|
120,000
USD
|
|
|
2020-03-02 |
2020-03-02 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
315
-0.5%
18.13
5,710
USD
|
315
-0.5%
|
18.13
|
5,710
USD
|
|
|
2020-03-02 |
2020-03-02 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
1,828
-2.7%
17.26
31,545
USD
|
1,828
-2.7%
|
17.26
|
31,545
USD
|
|
|
2020-02-26 |
2020-02-24 |
PS
Planned sale
|
Thomson Peter G.
VP Finance & Accounting
Officer
|
250
-0.9%
18.61
4,653
USD
|
250
-0.9%
|
18.61
|
4,653
USD
|
|
|
2020-02-26 |
2020-02-24 |
PS
Planned sale
|
Thomson Peter G.
VP Finance & Accounting
Officer
|
2,102
-6.8%
17.43
36,643
USD
|
2,102
-6.8%
|
17.43
|
36,643
USD
|
|
|
2020-02-26 |
2020-02-24 |
PS
Planned sale
|
Thomson Peter G.
VP Finance & Accounting
Officer
|
2,648
-7.9%
16.18
42,857
USD
|
2,648
-7.9%
|
16.18
|
42,857
USD
|
|
|
2020-02-20 |
2020-02-19 |
PS
Planned sale
|
Wallace Owen B.
Chief Scientific Officer
Officer
|
6,088
-4.6%
20.00
121,760
USD
|
6,088
-4.6%
|
20.00
|
121,760
USD
|
|
|
2020-02-20 |
2020-02-19 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
2,500
-0.4%
20.00
50,000
USD
|
2,500
-0.4%
|
20.00
|
50,000
USD
|
|
|
2020-02-05 |
2020-02-03 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
|
2,143
-3.0%
17.33
37,142
USD
|
2,143
-3.0%
|
17.33
|
37,142
USD
|
|
|
2020-01-27 |
2020-01-23 |
PS
Planned sale
|
Thomson Peter G.
VP Finance & Accounting
|
262
-0.8%
18.05
4,730
USD
|
262
-0.8%
|
18.05
|
4,730
USD
|
|
|
2020-01-27 |
2020-01-23 |
PS
Planned sale
|
Thomson Peter G.
VP Finance & Accounting
|
4,738
-12.3%
17.17
81,372
USD
|
4,738
-12.3%
|
17.17
|
81,372
USD
|
|
|
2019-07-23 |
2019-07-22 |
B
Purchase
|
Sanofi
Major owner
|
93,750
+20.2%
16.00
1,500,000
USD
|
93,750
+20.2%
|
16.00
|
1,500,000
USD
|
|
|
2019-07-22 |
2019-07-22 |
B
Purchase
|
Casdin Capital, LLC
Major owner
|
5,000
+0.8%
14.50
72,499
USD
|
5,000
+0.8%
|
14.50
|
72,499
USD
|
|
|
2019-07-22 |
2019-07-22 |
B
Purchase
|
Casdin Capital, LLC
Major owner
|
10,000
+1.7%
14.50
144,996
USD
|
10,000
+1.7%
|
14.50
|
144,996
USD
|
|
|
2019-07-22 |
2019-07-22 |
B
Purchase
|
Casdin Capital, LLC
Major owner
|
125,000
+26.9%
16.00
2,000,000
USD
|
125,000
+26.9%
|
16.00
|
2,000,000
USD
|
|
|
2019-07-22 |
2019-07-22 |
B
Purchase
|
Third Rock Ventures IV, L.P.
Major owner
|
81,250
+3.6%
16.00
1,300,000
USD
|
81,250
+3.6%
|
16.00
|
1,300,000
USD
|
|
